Atherothrombosis And Coronary Artery Disease Indian Edition

Written by the world’s foremost authorities, this volume provides comprehensive coverage of current approaches to the prevention, diagnosis, and management of atherothrombosis and its coronary and noncoronary complications. This edition has been thoroughly updated, sharply focused on clinical information, and trimmed to one manageable volume. Coverage begins with a review of risk factors and prevention, emphasizing lipid abnormalities, hypertension, smoking, diabetes, and obesity. Subsequent sections examine the pathogenesis of atherosclerosis, markers and imaging, acute coronary syndromes, chronic stable angina, and noncoronary atherothrombosis. Clinical presentations, medical management, and the latest interventional strategies are included.

Atherothrombosis refers to the coupling of atherosclerosis and thrombosis, and it is the leading cause of the majority of preventable deaths in the modern world. The medical, economic, social, and societal consequences or atherothrombosis are enormous, which make it a dynamic area for development of new pharmacologic agents. Atherothrombosis in Clinical Practice focuses upon the many clinical manifestations of atherothrombosis and therapies that presently exist, with a focus on evolving therapeutic approaches. First, atherothrombosis is defined and the epidemiology is explored. Then, the specific manifestations of atherothrombosis (coronary artery disease, valvular heart disease, cerebrovascular disease, atrial fibrillation, peripheral artery disease) are concisely covered by distinguished experts in the field. Next, specific medications are discussed, with an emphasis on innovative therapies and investigational agents including experimental lipid-modifying, anti-inflammatory, antiplatelet, and anticoagulant agents. State-of-the-art treatment of hypertension and diabetes is described succinctly. Lifestyle modification, medical therapies, and where appropriate, invasive modalities are discussed. Controversies in areas such as cholesterol management and glycemic control are summarized. Part of the Oxford American Cardiology Library, this handbook provides a practical, evidence-based summary of the condition and the most up-to-date research to equip clinicians in managing this common clinical problem.

Atherosclerosis is a subject of enormous contention for cardiologists and in general for all medical doctors. With this publication we have given you a concise "state-of-the-art" look at the world of atheroma. Many other elements could be included and so it is only a brief analysis of "today" (the preventive medicine era) and "tomorrow" (transforming the cure medicine era into the care medicine era) but also remembering "yesterday" (the ex-cathedra medicine era). Let's hope our arteries are free from atherosclerotic events: have a good read!

Atherothrombosis has reached pandemic proportions worldwide. It is the underlying condition that results in events leading to myocardial infarction, ischemic stroke and vascular death. As such, it is the leading cause of death worldwide manifested mainly as cardiovascular/cerebrovascular death. The complex and intimate relationship between atherothrombosis and traditional and novel risk factors is discussed in the following chapters of Traditional and Novel Risk Factors in Atherothrombosis - from basic science to clinical and therapeutic concerns. Beginning with pathology and pathophysiology of atherothrombosis, plaque rupture/disruption, this book continues with molecular, biochemical, inflammatory, cellular aspects and finally analyzes several aspects of clinical pharmacology.

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.